![]() To help keep communities safe from COVID-19, HHS remains committed to maximizing continued access to COVID-19 vaccines and treatments.Īt the end of the COVID-19 PHE on May 11, Americans will continue to be able to access COVID-19 vaccines at no cost, just as they have during the COVID-19 PHE, due to the requirements of the CDC COVID-19 Vaccination Program Provider Agreement. ![]() The Administration’s continued response to COVID-19 is not fully dependent on the emergency declaration for the COVID-19 PHE, and there are significant flexibilities and actions that will not be affected when we transition from the current phase of our response on May 11.Īccess to COVID-19 vaccinations and certain treatments, such as Paxlovid and Lagevrio, will generally not be affected. What will not be affected by the end of the COVID-19 PHE: And we are continuing to invest in efforts to better understand and address Long COVID and to help mitigate the impacts. We will continue to advance research into new, innovative vaccines and treatments through an investment of $5 billion in Project NextGen, a dedicated program to accelerate and streamline the rapid development of the next generation of vaccines and treatments, including investments in research, development, and manufacturing capacity and advancing critical science. To ensure an orderly transition, we have been working for months so that we can continue to meet the needs of those affected by COVID-19.Įven beyond the end of the COVID-19 PHE, we will continue to work to protect Americans from the virus and its worst impacts by supporting access to COVID-19 vaccines, treatments, and tests, including for people without health insurance. That is why our response to the spread of SARS-CoV-2, the virus that causes COVID-19, remains a public health priority. Still, we know so many people continue to be affected by COVID-19, particularly seniors, people who are immunocompromised, and people with disabilities.
0 Comments
Leave a Reply. |